Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 33527128.
- Also identified by DOI 10.1093/cid/ciaa785 and PMC identifier 7850546.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV protection and showed good sensitivity and specificity for detectable plasma tenofovir.
Medical subject headings
- Anti-HIV Agents
- HIV Infections
- Pre-Exposure Prophylaxis